LEO Pharma 
Welcome,         Profile    Billing    Logout  
 27 Products   63 Diseases   27 Products   80 Trials   3278 News 


«12345678910111213...4849»
  • ||||||||||  Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
    Molecular profile of interleukin-17RA blockade by brodalumab in Japanese patients with psoriasis (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1696;    
    These data suggested that IL-17RA blockade by brodalumab treatment induced rapid changes of the molecular profiling, such as IL17C, compared to baseline. Changes in the molecular profile of the lesions and their maintenance of a suppressed state may have led to the rapid clinical efficacy and high achievement rate of PASI score of 0 at 12 weeks.
  • ||||||||||  Efficacy and safety of biological drugs in the treatmens of moderate-to-severe psoriasis in elderly patients (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1657;    
    The results of the present analysis are in line with those of clinical trials randomised clinical trials in the general population and with those of retrospective studies in the elderly population. The data obtained support the hypothesis of the effectiveness of biologic drugs even in patients over 65 and support the appropriateness of their use in clinical practice.
  • ||||||||||  orismilast oral (LEO 32731) / UNION Therap
    Molecular effects in the skin of psoriasis patients after oral treatment with orismilast (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1622;    
    In addition, markers related to the increased risk of atherosclerotic cardiovascular disease are also reduced. Finally, the study underlines tape strip sampling of the skin as a powerful, non-invasive technology to obtain data on protein changes using the Olink
  • ||||||||||  Bimzelx (bimekizumab) / UCB
    Bimekizumab in severe refractory psoriasis in special locations and psoriatic arthritis. (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1608;    
    In addition, two of these patients had presented failure to different classes of biologics. In all of them there was an excellent response with bimekizumab, maintained at 16 weeks, as well as a rapid onset of action that begins in the first 3-4 weeks.
  • ||||||||||  Anti-interleukin biologics and tuberculosis: a narrative review (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1583;    
    Materials & A narrative review of the scientific literature was conducted, including real-life reports of psoriatic patients treated with one of the following drugs: Brodalumab, Ixekizumab, Secukinumab, Guselkumab, Risankizumab, Tildrakizumab, Ustekinumab. The overview offered by this literature review strengthens the safety data of anti-IL drugs for this patient population and offers critical insights on the evaluation of the risk/benefit ratio of anti-tuberculosis prophylaxis.
  • ||||||||||  Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis (e-Poster Hall) -  Aug 8, 2023 - Abstract #EADV2023EADV_1515;    
    This meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with very high rates for five-year guselkumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (real-world data vs. prescription databases) is relevant when interpreting drug survival studies.
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Hub 1.16 Tralokinumab  (Industry Experts Hub 1) -  Aug 3, 2023 - Abstract #EADV2023EADV_1192;    
    Sponsored by LEO Pharma Sponsored by LEO Pharma
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Tralokinumab experience from the real world  (Industry Experts Hub 1) -  Aug 3, 2023 - Abstract #EADV2023EADV_562;    
    Sponsored by LEO Pharma Sponsored by LEO Pharma
  • ||||||||||  Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
    Trial completion date, Trial primary completion date:  Residual Disease MEMory in PSOriasis Skin During EnstiLAR (clinicaltrials.gov) -  Aug 3, 2023   
    P4,  N=12, Recruiting, 
    Recommendations are made regarding the improvement of adverse event reporting to better understand the epidemiology of injection site reactions. Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Preclinical, Journal:  The Anti-Inflammatory and Skin Barrier Function Recovery Effects of Schisandra chinensis in Mice with Atopic Dermatitis. (Pubmed Central) -  Aug 2, 2023   
    Furthermore, unlike dexamethasone, EESC did not reduce the spleen/body weight ratio. These results suggest that S. chinensis can be used as an alternative to external corticosteroids and that its anti-inflammatory and skin barrier dysfunction-restoring effects are related to the downregulation of pro-inflammatory cytokines and chemokines, such as TNF-?, IL-4, IL-6, IL-8, and TSLP.
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Journal, IO biomarker:  Skin-derived TSLP stimulates skin migratory dendritic cells to promote the expansion of regulatory T cells. (Pubmed Central) -  Aug 1, 2023   
    We previously reported that the topical application of the vitamin D3 analog MC903 systemically expands Treg cells by stimulating the production of thymic stromal lymphopoietin (TSLP) from the skin...Together, these data demonstrate that vitamin D3 stimulation of skin induces TSLP expression, which stimulates skin migratory DCs to expand Treg cells. Thus, topical MC903 treatment could represent a convenient strategy to treat inflammatory disorders by engaging this pathway.
  • ||||||||||  Review, Journal:  Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments. (Pubmed Central) -  Jul 31, 2023   
    In detail, conventional and biologic systemic drugs demonstrated efficacy in recent trials, including acitretin, methotrexate, cyclosporine, apremilast, adalimumab, infliximab, etanercept, certolizumab, golimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab and tildrakizumab. Several therapies have demonstrated efficacy and safety in the treatment of NP; however, the choice of treatment depends not only on the severity of the nail involvement, but also on whether PsA is present, the patient's comorbidities other than PsA, previous treatment history, and the patient's drug preferences.
  • ||||||||||  orismilast oral (LEO 32731) / UNION Therap
    Review, Journal:  Psoriasis: a focus on upcoming oral formulations. (Pubmed Central) -  Jul 29, 2023   
    A great number of oral treatments with singular mechanism of action, like A3AR agonists, HSP90 inhibitors, ROCK-2 inhibitors, oral TNF inhibitors, oral IL-23 inhibitors, oral IL-17 inhibitors, PD4 inhibitors (orismilast) and several Tyk2 inhibitors, are currently being evaluated in clinical trials and could be suitable for approval in the future. Growing variation in treatment modes of administration will allow dermatologists to better integrate patient preferences in the therapeutic decision process.
  • ||||||||||  Review, Journal:  A Review of Existing and New Treatments for the Management of Hand Eczema. (Pubmed Central) -  Jul 27, 2023   
    Two major classes of drugs emerging for the treatment of hand eczema include IL-4/IL-13 inhibitors and JAK inhibitors. With the increase in efficacy seen with these new drugs, we are also noting improved adverse effect profiles, making them attractive options to add to a clinician's management toolbox for patients with hand eczema.
  • ||||||||||  Retrospective data, Review, Journal:  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (Pubmed Central) -  Jul 16, 2023   
    Living systematic reviews offer a new approach to review updating, in which the review is continually updated, incorporating relevant new evidence as it becomes available. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
  • ||||||||||  orismilast oral (LEO 32731) / UNION Therap
    Trial completion date, Trial primary completion date:  Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS) (clinicaltrials.gov) -  Jul 13, 2023   
    P2b,  N=210, Recruiting, 
    Please refer to the Cochrane Database of Systematic Reviews for the current status of this review. Trial completion date: Jul 2023 --> Feb 2024 | Trial primary completion date: Jun 2023 --> Jan 2024
  • ||||||||||  Trial primary completion date:  ACTIV-4: Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (clinicaltrials.gov) -  Jul 12, 2023   
    P4,  N=880, Active, not recruiting, 
    Brodalumab demonstrated high PASI and IGA responses and was well tolerated in clinical practice in plaque, scalp and palmoplantar psoriasis. Trial primary completion date: May 2023 --> Aug 2023
  • ||||||||||  Dovonex (calcipotriol) / LEO Pharma, Novartis
    Morphea Linier (En Coup De Sabre) In A 21 Year-Old Woman () -  Jul 3, 2023 - Abstract #WCD2023WCD_7039;    
    History of HZ may predict the occurrence of HZ during upadacitinib treatment in patients with AD. The patient had administered Daivonex